Screen Failure Sample Clauses
Screen Failure. A Screen Failure is a consented Trial Subject who fails to meet the screening visit criteria and is thus not eligible for enrolment into the Trial.
Screen Failure. Screen Failure je Subjekt hodnocení, který již udělil souhlas se zařazením do Studie a který nesplnil kritéria screeningové návštěvy a xxx není způsobilý k zařazení do Studie.
Screen Failure. In case of screening failure, the Visit 1-Screening fee and applicable specific procedure costs will be paid in accordance with sections 1.1 and 1.2 of this Exhibit A for the visit and the procedures performed in accordance with the Protocol. Fees are inclusive of overhead. Idorsia reserves the right to reasonably limit the number of screening failures payments by notifying previously IN WRITING the Institution and the Investigator.
Screen Failure. A Screen Failure (SF) is a consented Trial Subject who fails to meet the screening visit criteria and is thus not eligible for enrolment into the Trial. Screen Failures will be reimbursed by USD 315.30 per Trial Subject. The maximum No. of Screen Failures is 1 SF paid per 1 Randomized Trial Subject.
Screen Failure. F. Neúspešné vstupné vyšetrenia:
Screen Failure. Screen failures are defined as individuals who consent to participate in the clinical study but are not subsequently randomly assigned to the study treatment. A minimal set of screen failure information is required to ensure transparent reporting of screen failure subjects, to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements, and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, and any AEs and SAEs. Retesting of abnormal laboratory parameters can be done during the initial screening period at the discretion of the investigator in consultation with the Sponsor’s Medical Monitor (or designee). Subjects who are not enrolled into the study can be rescreened for inclusion in the study one additional time. These subjects will be assigned a new screening number; such subjects will be determined a permanent screen failure after the second screening determines the subject is ineligible.
Screen Failure. CRO will pay the Institution for all Study procedures as performed during a failed Screening visit. All screening visits will be paid. A screen failure is considered a Study Subject who signs the informed consent form and completes screening but did not fulfill all Protocol inclusion/exclusion criteria. To be eligible for reimbursement of screen payments, the Institution and Principal Investigator must: a) provide evidence that screening activities have been performed as documented in the Study Subject’s medical notes; b) have completed the screening log provided separately by CRO c) provide any additional information which may be reasonably requested by CRO/Sponsor or Sponsor’s designee to appropriately document the patient screening procedures.
Screen Failure. In case of screen failure or run-in failure, the applicable visit fees stated in section 1.1 above will be paid based on EDC completion for the visits performed in accordance with the Protocol. Idorsia reserves the right to reasonably limit the number of screening failure or run-in failure payments by notifying previously IN WRITING the Institution and the Investigator 1.6
Screen Failure. A Screen Failure shall be defined as a Study Participant who has signed an Informed Consent but could not be effectively included in the Study under the inclusion/exclusion criteria or for other reasons. A maximum of X Screen Failure shall be paid during the study at a rate of XXXXX per Screen Failure Subject. Pacienti, kteří neprojdou vstupními vyšetřeními: Pacienti, kteří neprojdou vstupními vyšetřeními, budou definováni jako účastníci studie, kteří podepsali informovaný souhlas, ale nebylo možné je skutečně zařadit podle zařazovacích/vylučovacích kritérií nebo z jiných důvodů. V rámci studie bude proplacen maximálně X pacient, který neprojde vstupními vyšetřeními, a to ve výši XXXXX za pacienta, který neprojde vstupními vyšetřeními.
Screen Failure. Any patient who was consented and entered into the screening process appropriately, but subsequently did not meet the entry criteria in order to be treated. Patients who fail screening will not be followed for safety or efficacy assessment, and no other study procedures will be performed. Evaluable Patient - Any patient who received the study drug. Lost to follow-up - A patient deemed to be lost to follow-up is any patient who received treatment, but who does not complete scheduled study visits. This includes those patients who withdraw consent and refuse further study participation and all attempts to contact the patient are deemed unsuccessful.